(Chairperson) Co-Founder & CEO, Avenzo

Athena Countouriotis is the Chair of Leal’s Board of Directors. She is co-founder, President, CEO and Chairperson of Avenzo Therapeutics. Previously she led Turning Point Therapeutics as President and CEO through its IPO in 2019 to its acquisition by Bristol Myers Squibb in 2022; during that time period, she and her team raised more than $1.2 billion across multiple equity financings. With over 20 years of industry experience, Dr. Countouriotis has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.